GlassScriptPhysician profile
Kady A Lato
NPI 1124485776
$6,730.02
in general payments reported to CMS, 2019-2025
28 companies · $2,064 in 2025
The $2,064 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,189 · 2022: $1,167 · 2023: $965 · 2024: $1,344 · 2025: $2,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,636 · Travel and Lodging: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,635.96 |
| Travel and Lodging | $737.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $3,062.49 | 2023-2025 | Xeomin |
| Abbvie INC. | $1,241.84 | 2021-2025 | |
| Novo Nordisk INC | $475.01 | 2021-2023 | Rybelsus, Ozempic |
| Bausch Health US, LLC | $471.60 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $305.07 | 2021-2023 | |
| Lilly USA, LLC | $164.76 | 2021-2023 | Mounjaro, Trulicity |
| Galderma Laboratories, L.P. | $130.76 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.27 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.46 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $79.34 | 2021-2022 | |
| Medtronic, INC. | $75.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $60.28 | 2022-2023 | Austedo |
| Amgen INC. | $54.51 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $51.54 | 2022 | |
| Daiichi Sankyo INC. | $45.73 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $32.83 | 2021 | |
| Shield Therapeutics INC | $29.85 | 2023 | Accrufer |
| Exact Sciences Corporation | $24.36 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $23.79 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $22.29 | 2022 | |
| Ibsa Pharma INC. | $20.40 | 2025 | Tirosint, Flector, Licart |
| Antares Pharma, INC. | $17.26 | 2022 | |
| Currax Pharmaceuticals LLC | $15.38 | 2025 | Contrave |
| Janssen Pharmaceuticals, INC | $14.70 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.56 | 2021 | |
| Sumitomo Pharma America, INC. | $7.21 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kady Lato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.